119 related articles for article (PubMed ID: 9293790)
41. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
Elgqvist J; Bernhardt P; Hultborn R; Jensen H; Karlsson B; Lindegren S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Mar; 46(3):464-71. PubMed ID: 15750160
[TBL] [Abstract][Full Text] [Related]
42. Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma.
Schillaci O; DeNardo GL; DeNardo SJ; Goldstein DS; Kroger LA; O'Donnell RT; Lamborn KR
Cancer Biother Radiopharm; 2007 Aug; 22(4):521-30. PubMed ID: 17803447
[TBL] [Abstract][Full Text] [Related]
43. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.
Kaminski MS; Zasadny KR; Francis IR; Milik AW; Ross CW; Moon SD; Crawford SM; Burgess JM; Petry NA; Butchko GM
N Engl J Med; 1993 Aug; 329(7):459-65. PubMed ID: 7687326
[TBL] [Abstract][Full Text] [Related]
44. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
Vallabhajosula S; Goldsmith SJ; Hamacher KA; Kostakoglu L; Konishi S; Milowski MI; Nanus DM; Bander NH
J Nucl Med; 2005 May; 46(5):850-8. PubMed ID: 15872360
[TBL] [Abstract][Full Text] [Related]
45. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
46. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
[TBL] [Abstract][Full Text] [Related]
47. Red marrow and blood dosimetry in (131)I treatment of metastatic thyroid carcinoma: pre-treatment versus in-therapy results.
Giostra A; Richetta E; Pasquino M; Miranti A; Cutaia C; Brusasco G; Pellerito RE; Stasi M
Phys Med Biol; 2016 Jun; 61(11):4316-26. PubMed ID: 27200493
[TBL] [Abstract][Full Text] [Related]
48. Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy.
DeNardo GL; Siantar CL; DeNardo SJ
Cancer Biother Radiopharm; 2002 Feb; 17(1):107-18. PubMed ID: 11915167
[TBL] [Abstract][Full Text] [Related]
49. Distribution of a breast-directed I-131-radiolabeled monoclonal antibody in blood and bone marrow: implications for radiation immunotherapy.
Johnson TK; Gonzalez R; Kasliwal RK; Lear JL; Feyerabend AJ; Dienhart DG; Ceriani RL; Bunn PA
Radiology; 1992 Jan; 182(1):107-14. PubMed ID: 1727271
[TBL] [Abstract][Full Text] [Related]
50. Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy.
Hartmann Siantar CL; DeNardo GL; DeNardo SJ
J Nucl Med; 2003 Aug; 44(8):1322-9. PubMed ID: 12902424
[TBL] [Abstract][Full Text] [Related]
51. Predicting myelotoxicity in radioimmunotherapy: what does dosimetry contribute?
Zanzonico P; Sgouros G
J Nucl Med; 1997 Nov; 38(11):1753-4. PubMed ID: 9374346
[No Abstract] [Full Text] [Related]
52. Prediction of iodine-131 biokinetics and radiation doses from therapy on the basis of tracer studies: an important question for therapy planning in nuclear medicine.
Willegaignon J; Pelissoni RA; Lima BC; Sapienza MT; Coura-Filho GB; Buchpiguel CA
Nucl Med Commun; 2016 May; 37(5):473-9. PubMed ID: 26671852
[TBL] [Abstract][Full Text] [Related]
53. Milestones in the development of Lym-1 therapy.
DeNardo GL; O'Donnell RT; Rose LM; Mirick GR; Kroger LA; DeNardo SJ
Hybridoma; 1999 Feb; 18(1):1-11. PubMed ID: 10211782
[TBL] [Abstract][Full Text] [Related]
54. Impact of splenomegaly on therapeutic response and I-131-LYM-1 dosimetry in patients with B-lymphocytic malignancies.
Shen S; DeNardo GL; O'Donnell RT; Yuan A; DeNardo DA; DeNardo SJ
Cancer; 1997 Dec; 80(12 Suppl):2553-7. PubMed ID: 9406709
[TBL] [Abstract][Full Text] [Related]
55. A mouse bone marrow dosimetry model.
Muthuswamy MS; Roberson PL; Buchsbaum DJ
J Nucl Med; 1998 Jul; 39(7):1243-7. PubMed ID: 9669402
[TBL] [Abstract][Full Text] [Related]
56. Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma.
Ferrer L; Malek E; Bodet-Milin C; Legouill S; Prangère T; Robu D; Jeans S; Tipping J; Huglo D; Carpentier P; Illidge T; Kraeber-Boderé F; Morschhauser F; Bardiès M
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):529-37. PubMed ID: 23358406
[TBL] [Abstract][Full Text] [Related]
57. A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebrae.
Meredith RF; Shen S; Forero A; LoBuglio A
J Nucl Med; 2008 Feb; 49(2):279-84. PubMed ID: 18199606
[TBL] [Abstract][Full Text] [Related]
58. Imaging and treatment of B-cell lymphoma.
Eary JF; Press OW; Badger CC; Durack LD; Richter KY; Addison SJ; Krohn KA; Fisher DR; Porter BA; Williams DL
J Nucl Med; 1990 Aug; 31(8):1257-68. PubMed ID: 2384792
[TBL] [Abstract][Full Text] [Related]
59. Radiation dose from human platelets labelled with indium 111.
van Reenen OR; Lötter MG; Minnaar PC; Heyns Adu P; Badenhorst PN; Pieters H
Br J Radiol; 1980 Aug; 53(632):790-5. PubMed ID: 6777011
[TBL] [Abstract][Full Text] [Related]
60. Importance of pre-treatment radiation absorbed dose estimation for radioimmunotherapy of non-Hodgkin's lymphoma.
Eary JF; Krohn KA; Press OW; Durack L; Bernstein ID
Nucl Med Biol; 1997 Oct; 24(7):635-8. PubMed ID: 9352534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
